Applications of (S)-1,4-Benzodioxan-2-Carboxypiperazine in Industrial Manufacturing

(S)-1,4-Benzodioxan-2-Carboxypiperazine serves specialized roles as an intermediate in advanced synthesis of pharmaceutical compounds and as a critical building block for select fine chemicals. As the manufacturer, we supply this material to global partners engaged in innovative downstream processes where strict regulatory adherence, formulation discipline, and stepwise process integration are essential. Below we present key application scenarios illustrating real-world use in the chemical and pharmaceutical value chain.

1. Advanced Intermediate in Central Nervous System (CNS) Drug Synthesis

Downstream pharmaceutical companies utilize this chiral intermediate to construct piperazine-based CNS-active small molecules, often as part of multi-step synthetic routes targeting selective receptor modulation. Its stereopurity is imperative when entering late-stage reaction sequences that form the pharmacologically active motifs required by regulatory authorities. The downstream sector incorporates this intermediate to streamline production of active pharmaceutical ingredients (APIs) for investigational and approved therapies.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP/NF and Ph. Eur. monographs for APIs (specifically chiral purity and impurity thresholds)
• 21 CFR Part 211 Current Good Manufacturing Practice (cGMP) regulations
• EMA guideline on the specification limits for residues of metal catalysts or metal reagents

Typical usage ratio

• Used as a key intermediate, typically 1.1–1.4 equivalents relative to the primary coupling partner, with adjustment based on target yield and route selectivity

Downstream process integration

• Introduced at the advanced stage of the chemical synthesis pathway after initial backbone construction, ensuring correct chiral centers before final ring closure or functionalization
• High-purity batches dispensed directly into multi-step coupling reactions managed under validated pharmaceutical manufacturing protocols

Final product types

• Central nervous system APIs such as serotonin receptor modulators and investigational antipsychotic agents
• Small-molecule chiral intermediates for CNS therapeutic drug candidates

2. Intermediate for Oncology Drug Development

Within the oncology sector, this material acts as a foundational intermediate for targeted anticancer drug synthesis, enabling attachment of structurally precise side chains to establish high-affinity ligands. Oncology molecule design often demands stringent stereochemical fidelity, where improper incorporation affects receptor binding and therapeutic index. Our customers consistently require detailed analytical documentation to ensure this intermediate meets phase-appropriate preclinical and clinical development standards.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• FDA Guidance for Industry: ANDAs – APIs, Stability, and Impurity Testing
• ISO 9001:2015 Quality Management Systems (applied to synthesis QC)
• Global pharmacopoeial references (pre-IND documentation for clinical trials)

Typical usage ratio

• Varies between 0.8–1.2 equivalents, with precise ratio determined during process optimization for target molecule scaffolding

Downstream process integration

• Enters the synthesis after initial aryl or heterocyclic assembly; incorporated by nucleophilic substitution or amidation to build molecular complexity
• Steric configuration monitored by chiral HPLC and NMR at every reaction step

Final product types

• Precursor molecules for tyrosine kinase inhibitors
• API candidates for targeted chemotherapy

3. Starting Material for Fine Chemical Synthesis in Chiral Catalysts

Specialized downstream manufacturers employ this molecule as a starting unit in the design of advanced chiral ligands and catalysts essential for high-precision asymmetric transformations. Its incorporation ensures batch-to-batch reproducibility fundamental to producing fine chemicals with narrowly defined stereochemical outcomes. Fine chemical producers require granular batch traceability and validated handling procedures throughout.

Industry compliance standards

• ISO 17034 Reference Material Producer accreditation
• ISO 14001:2015 Environmental Management Systems (applicable during processing and waste management)
• REACH Regulation (EC) No 1907/2006—Registration, Evaluation, Authorisation, and Restriction of Chemicals
• In-house validated analytical protocols for stereochemical purity

Typical usage ratio

• Between 5% and 30% by weight in the catalyst formulation, adapted to the specific type of chiral ligand being synthesized

Downstream process integration

• Added during the initial coupling or cyclization to introduce rigid chiral frameworks, before functional group derivatization
• Monitored by chromatography for verification of ligand architecture consistency

Final product types

• Chiral phosphine ligands for asymmetric hydrogenation processes
• Chiral catalyst auxiliaries for agrochemical and pharmaceutical manufacturing

4. Precursor for Specialty Analytical Reference Compound Synthesis

Producers of certified reference materials utilize this compound as a precursor for the preparation of traceable analytical standards, particularly for regulatory and forensic laboratory testing. The need for absolute stereochemical and chemical identity traceability governs all synthesis and documentation protocols. Margin for deviation is practically nonexistent, as end-users deploy reference standards for both qualitative and quantitative instrument calibration.

Industry compliance standards

• ISO/IEC 17025 General requirements for the competence of testing and calibration laboratories
• ISO Guide 34 (replaced by ISO 17034:2016) for reference material producers
• USP General Chapter <1224> Certified Reference Materials
• FDA Part 211 on analytical laboratory controls

Typical usage ratio

• Employed as the main substance with conversion rates near analytical stoichiometry (conversion factor approaches 1:1 for target reference material)

Downstream process integration

• Forms the structural core in analytical reference synthesis, introduced as the unique chiral entity, with minimal chemical transformation to retain molecular integrity
• End-point verification by chiral purity, NMR, MS, and melting point analysis

Final product types

• Certified pharmaceutical impurity standards
• Analytical calibration samples for HPLC and GC